Showing results (11-20 of 62) with videos related to
Sort By:
Pageof 7
Cancer Biology & Therapy|August 13, 2002
Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genesMilos Dokmanovic, Bey-Dih Chang, Jing Fang, et al.Molecular Cancer Therapeutics|June 11, 2009
Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancerMilos Dokmanovic, Dianne S Hirsch, Yi Shen, et al.Expert Opinion on Drug Metabolism & Toxicology|June 3, 2017
Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumabMilos Dokmanovic, Kathryn E King, Nishant Mohan, et al.Molecular Cancer Therapeutics|April 14, 2011
Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistanceMilos Dokmanovic, Yi Shen, Tabetha M Bonacci, et al.Cancer Research|September 5, 2006
Agonist and antagonist of retinoic acid receptors cause similar changes in gene expression and induce senescence-like growth arrest in MCF-7 breast carcinoma cellsYuhong Chen, Milos Dokmanovic, Wilfred D Stein, et al.Cellular Signalling|July 24, 2012
Small GTPase Rho regulates R-cadherin through Dia1/profilin-1Tabetha M Bonacci, Dianne S Hirsch, Yi Shen, et al.Oncotarget|July 14, 2016
VPS34 regulates TSC1/TSC2 heterodimer to mediate RheB and mTORC1/S6K1 activation and cellular transformationNishant Mohan, Yi Shen, Milos Dokmanovic, et al.Cancer Biology & Therapy|May 20, 2014
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibitionMilos Dokmanovic, Yun Wu, Yi Shen, et al.Seminars in Cancer Biology|November 11, 2006
Thioredoxin in cancer--role of histone deacetylase inhibitorsPaul A MarksCell Cycle (Georgetown, Tex.)|March 17, 2004
The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)Paul A MarksPageof 7